Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Chintharlapalli, Sudhakar ^a,c   Papineni, Sabitha ^a,d   Lei, Ping ^a   Pathi, Satya ^b   Safe, Stephen ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d DOW AGROSCIENCES LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETULIC ACID; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; GENE PRODUCT; MESSENGER RNA; MICRORNA; MICRORNA 27A; PROTEASOME; REACTIVE OXYGEN METABOLITE; SECURIN; SURVIVIN; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; TRANSCRIPTION FACTOR SP4; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; MIRN27 MICRORNA, HUMAN; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR SP; TRITERPENE; ZBTB10 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL ASSAY; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; COLON TUMOR; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; MICRORNAS; PROTEASOME ENDOPEPTIDASE COMPLEX; REAL-TIME POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; SP TRANSCRIPTION FACTORS; TRITERPENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052024865     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-371     Document Type: Article

References (49)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
2. Fearnhead NS, Wilding JL, Bodmer WF. Genetics of colorectal cancer: hereditary aspects and overview of colorectal tumorigenesis. Br Med Bull 2002, 64:27-43. 10.1093/bmb/64.1.27, 12421723.
3. Debinski HS, Love S, Spigelman AD, Phillips RK. Colorectal polyp counts and cancer risk in familial adenomatous polyposis. Gastroenterology 1996, 110:1028-1030. 10.1053/gast.1996.v110.pm8612989, 8612989.
4. Spirio L, Olschwang S, Groden J, Robertson M, Samowitz W, Joslyn G, Gelbert L, Thliveris A, Carlson M, Otterud B. Alleles of the APC gene: an attenuated form of familial polyposis. Cell 1993, 75:951-957. 10.1016/0092-8674(93)90538-2, 8252630.
5. Tomlinson IP, Hampson R, Karran P, Bodmer WF. DNA mismatch repair in lymphoblastoid cells from hereditary non-polyposis colorectal cancer (HNPCC) patients is normal under conditions of rapid cell division and increased mutational load. Mutat Res 1997, 383:177-182.
6. Borresen AL, Lothe RA, Meling GI, Lystad S, Morrison P, Lipford J, Kane MF, Rognum TO, Kolodner RD. Somatic mutations in the hMSH2 gene in microsatellite unstable colorectal carcinomas. Human Mol Genet 1995, 4:2065-2072.
7. Liu B, Nicolaides NC, Markowitz S, Willson JK, Parsons RE, Jen J, Papadopolous N, Peltomaki P, de la Chapelle A, Hamilton SR. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet 1995, 9:48-55. 10.1038/ng0195-48, 7704024.
8. Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, Peltomaki P, Mecklin JP, Jarvinen HJ. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999, 81:214-218. 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO;2-L, 10188721.
9. Haenszel W, Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 1968, 40:43-68.
10. Whittemore AS, Zheng S, Wu A, Wu ML, Fingar T, Jiao DA, Ling CD, Bao JL, Henderson BE, Paffenbarger RS. Colorectal cancer in Chinese and Chinese-Americans. Natl Cancer Inst Monogr 1985, 69:43-46.
11. Michels KB, Giovannucci E, Chan AT, Singhania R, Fuchs CS, Willett WC. Fruit and vegetable consumption and colorectal adenomas in the Nurses' Health Study. Cancer Res 2006, 66:3942-3953. 10.1158/0008-5472.CAN-05-3637, 16585224.
12. Liang W, Binns CW. Fruit, vegetables, and colorectal cancer risk: the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 2009, 90:1112-1114.
13. Kim DH, Smith-Warner SA, Spiegelman D, Yaun SS, Colditz GA, Freudenheim JL, Giovannucci E, Goldbohm RA, Graham S, Harnack L, et al. Pooled analyses of 13 prospective cohort studies on folate intake and colon cancer. Cancer Causes Control 2010, 21:1919-1930. 10.1007/s10552-010-9620-8, 20820900.
14. Eussen SJ, Vollset SE, Igland J, Meyer K, Fredriksen A, Ueland PM, Jenab M, Slimani N, Boffetta P, Overvad K, et al. Plasma folate, related genetic variants, and colorectal cancer risk in EPIC. Cancer Epidemiol Biomarkers Prev 2010, 19:1328-1340. 10.1158/1055-9965.EPI-09-0841, 2880712, 20447924.
15. Chawla AK, Kachnic LA, Clark JW, Willett CG. Combined modality therapy for rectal and colon cancer. Semin Oncol 2003, 30:101-112.
16. Cascinu S, Georgoulias V, Kerr D, Maughan T, Labianca R, Ychou M. Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors. Ann Oncol 2003, 14(Suppl 2):ii25-ii29.
17. Chau I, Cunningham D. Adjuvant therapy in colon cancer: current status and future directions. Cancer Treat Rev 2002, 28:223-236. 10.1016/S0305-7372(02)00047-6, 12435370.
18. Abdelrahim M, Safe S. Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expession in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins. Mol Pharmacol 2005, 68:317-329.
19. Abdelrahim M, Baker CH, Abbruzzese JL, Safe S. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 2006, 98:855-868. 10.1093/jnci/djj232, 16788159.
20. Chintharlapalli S, Papineni S, Ramaiah SK, Safe S. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res 2007, 67:2816-2823. 10.1158/0008-5472.CAN-06-3735, 17363604.
21. Chadalapaka G, Jutooru I, Chintharlapalli S, Papineni S, Smith R, Li X, Safe S. Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res 2008, 68:5345-5354. 10.1158/0008-5472.CAN-07-6805, 2587449, 18593936.
22. Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S. The oncogenic microRNA-27a targets genes that regulate specificity protein (Sp) transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res 2007, 67:11001-11011. 10.1158/0008-5472.CAN-07-2416, 18006846.
23. Papineni S, Chintharlapalli S, Abdelrahim M, Lee SO, Burghardt R, Abudayyeh A, Baker C, Herrera L, Safe S. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis 2009, 30:1193-1201. 10.1093/carcin/bgp092, 2704282, 19406933.
24. Yao JC, Wang L, Wei D, Gong W, Hassan M, Wu TT, Mansfield P, Ajani J, Xie K. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 2004, 10:4109-4117. 10.1158/1078-0432.CCR-03-0628, 15217947.
25. Jiang NY, Woda BA, Banner BF, Whalen GF, Dresser KA, Lu D. Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2008, 17:1648-1652. 10.1158/1055-9965.EPI-07-2791, 18628415.
26. Ammendola R, Mesuraca M, Russo T, Cimino F. Sp1 DNA binding efficiency is highly reduced in nuclear extracts from aged rat tissues. J Biol Chem 1992, 267:17944-17948.
27. Adrian GS, Seto E, Fischbach KS, Rivera EV, Adrian EK, Herbert DC, Walter CA, Weaker FJ, Bowman BH. YY1 and Sp1 transcription factors bind the human transferrin gene in an age-related manner. J Gerontol A Biol Sci Med Sci 1996, 51:B66-B75.
28. Oh JE, Han JA, Hwang ES. Downregulation of transcription factor, Sp1, during cellular senescence. Biochem Biophys Res Commun 2007, 353:86-91. 10.1016/j.bbrc.2006.11.118, 17161377.
29. Abdelrahim M, Smith III R, Burghardt R, Safe S. Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res 2004, 64:6740-6749. 10.1158/0008-5472.CAN-04-0713, 15374992.
30. Abdelrahim M, Baker CH, Abbruzzese JL, Sheikh-Hamad D, Liu S, Cho SD, Yoon K, Safe S. Regulation of vascular endothelial growth factor receptor-1 (VEGFR1) expression by specificity proteins 1, 3 and 4 in pancreatic cancer cells. Cancer Res 2007, 67:3286-3294. 10.1158/0008-5472.CAN-06-3831, 17409437.
31. Higgins KJ, Abdelrahim M, Liu S, Yoon K, Safe S. Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp proteins. Biochem Biophys Res Commun 2006, 345:292-301. 10.1016/j.bbrc.2006.04.111, 16678129.
32. Chadalapaka G, Jutooru I, Burghardt R, Safe S. Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells. Mol Cancer Res 2010, 8:739-750. 10.1158/1541-7786.MCR-09-0493, 2872686, 20407012.
33. Jutooru I, Chadalapaka G, Abdelrahim M, Basha MR, Samudio I, Konopleva M, Andreeff M, Safe SH. Methyl 2-Cyano-3,12-dioxooleana-1,9-dien-28-oate (CDDO-Me) decreases specificity protein (Sp) transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a. Mol Pharmacol 2010, 78:226-236. 10.1124/mol.110.064451, 2917860, 20488920.
34. Jutooru I, Chadalapaka G, Lei P, Safe S. Inhibition of NFκB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein downregulation. J Biol Chem 2010, 285:25332-25344. 10.1074/jbc.M109.095240, 2919096, 20538607.
35. Chintharlapalli S, Papineni S, Lee SO, Lei P, Jin U-H, Sherman SI, Santarpia L, Safe S. Inhibition of pituitary tumor-transforming gene-1 in thyroid cancer cells by drugs that decrease specificity proteins. Mol Carcinog
36. Chintharlapalli S, Papineni S, Abdelrahim M, Abudayyeh A, Abudayyeh A, Jutooru I, Chadalapaka G, Wu F, Mertens-Talcott SU, Vanderlaag K, et al. Oncogenic microRNA-27a is a target for anticancer agent methyl 2-cyano-3,11-dioxo-18β-olean-1,12-dien-30-oate in colon cancer cells. Int J Cancer 2009, 125:1965-1974. 10.1002/ijc.24530, 2766353, 19582879.
37. Jutooru I, Chadalapaka G, Sreevalsan S, Lei P, Barhoumi R, Burghardt R, Safe S. Arsenic trioxide downregulation of specificity protein (Sp) transcription factors in bladder cancer cells is dependent on reactive oxygen species (ROS). Exper Cell Res 2010, 316:2174-2188.
38. Pathi SS, Jutooru I, Chadalapaka G, Sreevalsan S, Anand S, Thatcher GR, Safe SH. GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species (ROS)-microRNA-27a:ZBTB10-specificity protein (Sp) pathway. Mol Cancer Res 2010, 9:195-202. 10.1186/1476-4598-9-195, 21156786.
39. Fulda S. Betulinic acid for cancer treatment and prevention. Int J Mol Sci 2008, 9:1096-1107. 10.3390/ijms9061096, 2658785, 19325847.
40. Fulda S, Kroemer G. Targeting mitochondrial apoptosis by betulinic acid in human cancers. Drug Discov Today 2009, 14:885-890. 10.1016/j.drudis.2009.05.015, 19520182.
41. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004, 23:4051-4060. 10.1038/sj.emboj.7600385, 524334, 15372072.
42. Pisha E, Chai H, Lee IS, Chagwedera TE, Farnsworth NR, Cordell GA, Beecher CW, Fong HH, Kinghorn AD, Brown DM. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med 1995, 1:1046-1051. 10.1038/nm1095-1046, 7489361.
43. Mullauer FB, van BL, Daalhuisen JB, Ten Brink MS, Storm G, Medema JP, Schiffelers RM, Kessler JH. Betulinic acid delivered in liposomes reduces growth of human lung and colon cancers in mice without causing systemic toxicity. Anticancer Drugs 2011, 22:223-233. 10.1097/CAD.0b013e3283421035, 21263311.
44. Mullauer FB, Kessler JH, Medema JP. Betulinic acid induces cytochrome c release and apoptosis in a Bax/Bak-independent, permeability transition pore dependent fashion. Apoptosis 2009, 14:191-202. 10.1007/s10495-008-0290-x, 19115109.
45. Takada Y, Aggarwal BB. Betulinic acid suppresses carcinogen-induced NF-kappa B activation through inhibition of I kappa B alpha kinase and p65 phosphorylation: abrogation of cyclooxygenase-2 and matrix metalloprotease-9. J Immunol 2003, 171:3278-3286.
46. Jung GR, Kim KJ, Choi CH, Lee TB, Han SI, Han HK, Lim SC. Effect of betulinic acid on anticancer drug-resistant colon cancer cells. Basic Clin Pharmacol Toxicol 2007, 101:277-285. 10.1111/j.1742-7843.2007.00115.x, 17845510.
47. Gao Y, Jia Z, Kong X, Li Q, Chang DZ, Wei D, Le X, Suyun H, Huang S, Wang L, et al. Combining betulinic acid and mithramycin A effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Cancer Res 2011, 71:5182-5193. 10.1158/0008-5472.CAN-10-2016, 21673052.
48. Dehelean CA, Feflea S, Ganta S, Amiji M. Anti-angiogenic effects of betulinic acid administered in nanoemulsion formulation using chorioallantoic membrane assay. J Biomed Nanotechnol 2011, 7:317-324. 10.1166/jbn.2011.1297, 21702370.
49. Li Q, Li Y, Wang X, Fang X, He K, Guo X, Zhan Z, Sun C, Jin YH. Co-treatment with ginsenoside Rh2 and betulinic acid synergistically induces apoptosis in human cancer cells in association with enhanced capsase-8 activation, bax translocation, and cytochrome c release. Mol Carcinog